Literature DB >> 23296925

In vitro transcription of long RNA containing modified nucleosides.

Norbert Pardi1, Hiromi Muramatsu, Drew Weissman, Katalin Karikó.   

Abstract

The in vitro synthesis of long RNA can be accomplished using phage RNA polymerase and template DNA. However, the in vitro synthesized RNA, unlike those transcribed in vivo in cells, lacks nucleoside modifications. Introducing modified nucleosides into in vitro transcripts is important because they reduce the potential of RNA to activate RNA sensors and translation of such nucleoside-modified RNA is increased in cell lines, primary cells, and after in vivo delivery. Here, we describe the in vitro synthesis of nucleoside-modified RNA with enhanced translational capacity and reduced ability to activate immune sensors.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23296925     DOI: 10.1007/978-1-62703-260-5_2

Source DB:  PubMed          Journal:  Methods Mol Biol        ISSN: 1064-3745


  51 in total

Review 1.  mRNA as a Transformative Technology for Vaccine Development to Control Infectious Diseases.

Authors:  Giulietta Maruggi; Cuiling Zhang; Junwei Li; Jeffrey B Ulmer; Dong Yu
Journal:  Mol Ther       Date:  2019-02-07       Impact factor: 11.454

Review 2.  mRNA vaccines - a new era in vaccinology.

Authors:  Norbert Pardi; Michael J Hogan; Frederick W Porter; Drew Weissman
Journal:  Nat Rev Drug Discov       Date:  2018-01-12       Impact factor: 84.694

3.  Nucleoside-modified mRNA vaccination partially overcomes maternal antibody inhibition of de novo immune responses in mice.

Authors:  Elinor Willis; Norbert Pardi; Kaela Parkhouse; Barbara L Mui; Ying K Tam; Drew Weissman; Scott E Hensley
Journal:  Sci Transl Med       Date:  2020-01-08       Impact factor: 17.956

4.  Human Cytomegalovirus Glycoprotein B Nucleoside-Modified mRNA Vaccine Elicits Antibody Responses with Greater Durability and Breadth than MF59-Adjuvanted gB Protein Immunization.

Authors:  Cody S Nelson; Jennifer A Jenks; Norbert Pardi; Matthew Goodwin; Hunter Roark; Whitney Edwards; Jason S McLellan; Justin Pollara; Drew Weissman; Sallie R Permar
Journal:  J Virol       Date:  2020-04-16       Impact factor: 5.103

5.  Lipid Nanoparticle-Delivered Chemically Modified mRNA Restores Chloride Secretion in Cystic Fibrosis.

Authors:  Ema Robinson; Kelvin D MacDonald; Kai Slaughter; Madison McKinney; Siddharth Patel; Conroy Sun; Gaurav Sahay
Journal:  Mol Ther       Date:  2018-06-15       Impact factor: 11.454

6.  Genetic and epigenetic modification of human primary NK cells for enhanced antitumor activity.

Authors:  Meisam Naeimi Kararoudi; Brian P Tullius; Nitin Chakravarti; Emily J Pomeroy; Branden S Moriarity; Kathie Beland; Aurelien B L Colamartino; Elie Haddad; Yaya Chu; Mitchell S Cairo; Dean A Lee
Journal:  Semin Hematol       Date:  2020-11-19       Impact factor: 3.851

7.  Nucleoside-modified mRNA encoding HSV-2 glycoproteins C, D, and E prevents clinical and subclinical genital herpes.

Authors:  Sita Awasthi; Lauren M Hook; Norbert Pardi; Fushan Wang; Arpita Myles; Michael P Cancro; Gary H Cohen; Drew Weissman; Harvey M Friedman
Journal:  Sci Immunol       Date:  2019-09-20

8.  Expression kinetics of nucleoside-modified mRNA delivered in lipid nanoparticles to mice by various routes.

Authors:  Norbert Pardi; Steven Tuyishime; Hiromi Muramatsu; Katalin Kariko; Barbara L Mui; Ying K Tam; Thomas D Madden; Michael J Hope; Drew Weissman
Journal:  J Control Release       Date:  2015-08-08       Impact factor: 9.776

Review 9.  Viral and Synthetic RNA Vector Technologies and Applications.

Authors:  Juliane W Schott; Michael Morgan; Melanie Galla; Axel Schambach
Journal:  Mol Ther       Date:  2016-07-05       Impact factor: 11.454

10.  PECAM-1 directed re-targeting of exogenous mRNA providing two orders of magnitude enhancement of vascular delivery and expression in lungs independent of apolipoprotein E-mediated uptake.

Authors:  Hamideh Parhiz; Vladimir V Shuvaev; Norbert Pardi; Makan Khoshnejad; Raisa Yu Kiseleva; Jacob S Brenner; Thomas Uhler; Steven Tuyishime; Barbara L Mui; Ying K Tam; Thomas D Madden; Michael J Hope; Drew Weissman; Vladimir R Muzykantov
Journal:  J Control Release       Date:  2018-10-15       Impact factor: 9.776

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.